Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
Cancer and its treatment can cause problems with attention, memory, and learning. These cognitive difficulties may affect your daily activities and worsen your quality of life.
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
Researchers want to find the best dose of the antibody-drug conjugate LY4101174 to treat advanced bladder and prostate cancers. The people in this study have bladder or prostate cancer that came back or keeps growing after treatment. 
Researchers want to learn how well zelenectide pevedotin works against advanced breast cancer. The people in this study have breast cancer that has come back, spread, or cannot be surgically removed. Their cancers are hormone receptor positive/HER2-negative or are triple negative. In addition, their tumor cells have an amplification (too many copies) of a gene called Nectin4.
Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).
Researchers want to find the best dose of TTI-101 that can be used safely alone and with other drugs for cancer. The people in this study have hepatocellular carcinoma (liver cancer) that has metastasized (spread) or is inoperable (surgically unremovable).
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
Researchers are studying how casdatifan, alone or with zimberelimab, works in people with kidney cancer. The people in this study have clear cell renal cell carcinoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
